Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...

As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Pfizer Inc. (PFE) named oncology chief and company veteran Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been ...

Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and ...

Pfizer (PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, ...

Pfizer (PFE) appoints Chris Boshoff as its new Chief Scientific Officer and President, R&D to replace the outgoing science ...

Boshoff replaces Mikael Dolsten, who led research and development at the drug giant for 15 years and who announced his plans to retire in July. The news may disappoint some investors, who may have ...